CA2164866A1 - Treatment of neuromuscular disorders and conditions with different botulinum serotype - Google Patents

Treatment of neuromuscular disorders and conditions with different botulinum serotype

Info

Publication number
CA2164866A1
CA2164866A1 CA002164866A CA2164866A CA2164866A1 CA 2164866 A1 CA2164866 A1 CA 2164866A1 CA 002164866 A CA002164866 A CA 002164866A CA 2164866 A CA2164866 A CA 2164866A CA 2164866 A1 CA2164866 A1 CA 2164866A1
Authority
CA
Canada
Prior art keywords
treatment
conditions
patient
botulinum serotype
neuromuscular disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002164866A
Other languages
French (fr)
Other versions
CA2164866C (en
Inventor
K. Roger Aoki
Michael W. Grayston
Steven R. Carlson
Judith M. Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
K. Roger Aoki
Michael W. Grayston
Steven R. Carlson
Judith M. Leon
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K. Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon, Allergan, Inc. filed Critical K. Roger Aoki
Priority to CA002310845A priority Critical patent/CA2310845C/en
Priority to CA002332406A priority patent/CA2332406C/en
Publication of CA2164866A1 publication Critical patent/CA2164866A1/en
Application granted granted Critical
Publication of CA2164866C publication Critical patent/CA2164866C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A method of treating a patient suffering from a disease, disorder or condition includes the administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient a therapeutically effective amount of another botulinum toxin of a different serotype.
CA002164866A 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype Expired - Lifetime CA2164866C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002310845A CA2310845C (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype
CA002332406A CA2332406C (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7504893A 1993-06-10 1993-06-10
US08/075,048 1993-06-10
PCT/US1994/006397 WO1994028922A1 (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CA002310845A Division CA2310845C (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype
CA002332406A Division CA2332406C (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype

Publications (2)

Publication Number Publication Date
CA2164866A1 true CA2164866A1 (en) 1994-12-22
CA2164866C CA2164866C (en) 2001-09-11

Family

ID=22123211

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002332406A Expired - Lifetime CA2332406C (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype
CA002310845A Expired - Lifetime CA2310845C (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype
CA002164866A Expired - Lifetime CA2164866C (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA002332406A Expired - Lifetime CA2332406C (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype
CA002310845A Expired - Lifetime CA2310845C (en) 1993-06-10 1994-06-07 Treatment of neuromuscular disorders and conditions with different botulinum serotype

Country Status (9)

Country Link
US (3) US6872397B2 (en)
EP (7) EP1099445A3 (en)
JP (4) JPH08511536A (en)
AU (1) AU689115B2 (en)
CA (3) CA2332406C (en)
DE (6) DE69435284D1 (en)
ES (5) ES2341140T3 (en)
HK (1) HK1061648A1 (en)
WO (1) WO1994028922A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
JP3510886B2 (en) * 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド Pharmaceutical composition containing botulinum B complex
EP1099445A3 (en) * 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
EP1147776B1 (en) * 1993-12-28 2010-12-15 Allergan, Inc. Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
AU6034396A (en) * 1995-06-06 1996-12-24 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
JP2002501033A (en) 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ Biologically active hemagglutinin of Clostridium botulinum type A and its use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2003272800A1 (en) * 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
AU2004216901B2 (en) * 2003-03-06 2009-11-12 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20080274480A1 (en) * 2004-08-04 2008-11-06 Allergan, Inc. Botulinum Toxin Type a Immunoresistant Assay
JP5089388B2 (en) 2004-09-01 2012-12-05 アラーガン、インコーポレイテッド Degradable clostridial toxin
EP1871789B1 (en) * 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
WO2008036060A2 (en) 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
EP1906923B1 (en) 2005-07-22 2018-01-24 The Foundry, LLC Systems and methods for delivery of a therapeutic agent
US7655243B2 (en) * 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
EP2001902B1 (en) 2006-03-14 2013-03-27 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
AR061669A1 (en) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
WO2009123174A1 (en) * 2008-03-31 2009-10-08 財団法人化学及血清療法研究所 Preparation of type a2 botulinum neurotoxin
EP2662046B1 (en) 2008-05-09 2023-03-15 Nuvaira, Inc. Systems and assemblies for treating a bronchial tree
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
CN107049479B (en) 2009-10-27 2020-10-16 努瓦拉公司 Delivery device with coolable energy emitting assembly
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
KR101820542B1 (en) 2009-11-11 2018-01-19 호라이라 인코포레이티드 Systems, apparatuses, and methods for treating tissue and controlling stenosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
JP6470678B2 (en) 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド Compound (II) that inhibits neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
JP6601922B2 (en) 2015-01-09 2019-11-06 イプセン バイオイノベーション リミテッド Cationic neurotoxin
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
CN109790204A (en) 2016-09-29 2019-05-21 益普生生物制药有限公司 Heterozygosis neurotoxin
CN111465352B (en) 2018-02-26 2024-04-12 益普生生物制药有限公司 Injection of non-cytotoxic proteases using ultrasound guidance
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5401243A (en) 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
FR2692475B1 (en) 1992-06-19 2000-04-21 Montpellier Chirurgie TOTAL KNEE PROSTHESIS.
JP3510886B2 (en) * 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド Pharmaceutical composition containing botulinum B complex
EP1099445A3 (en) * 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
EP1147776B1 (en) 1993-12-28 2010-12-15 Allergan, Inc. Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms

Also Published As

Publication number Publication date
DE69435253D1 (en) 2009-12-31
EP1941898A3 (en) 2008-11-05
EP1374886A2 (en) 2004-01-02
HK1061648A1 (en) 2004-09-30
EP1512411B1 (en) 2009-11-18
WO1994028922A1 (en) 1994-12-22
EP1374886A3 (en) 2004-02-11
CA2332406A1 (en) 1994-12-22
JP2005281317A (en) 2005-10-13
US20050129716A1 (en) 2005-06-16
EP1099445A2 (en) 2001-05-16
EP1508336A1 (en) 2005-02-23
EP0702561B1 (en) 2002-01-09
US6872397B2 (en) 2005-03-29
EP1508336B1 (en) 2009-11-18
ES2329232T3 (en) 2009-11-24
DE69435254D1 (en) 2009-12-31
EP1374886B1 (en) 2009-09-02
CA2310845A1 (en) 1994-12-22
EP1941898A2 (en) 2008-07-09
AU7087894A (en) 1995-01-03
US20020010138A1 (en) 2002-01-24
DE122009000066I2 (en) 2010-12-30
EP0702561A1 (en) 1996-03-27
ES2168302T3 (en) 2002-06-16
JP2010111703A (en) 2010-05-20
ES2335662T3 (en) 2010-03-31
AU689115B2 (en) 1998-03-26
EP1512411A1 (en) 2005-03-09
DE69429619T2 (en) 2002-09-12
JP2011256193A (en) 2011-12-22
EP1166793A1 (en) 2002-01-02
EP1941898B1 (en) 2010-03-17
US20010012833A1 (en) 2001-08-09
ES2335281T3 (en) 2010-03-24
DE69435235D1 (en) 2009-10-15
EP1099445A3 (en) 2001-09-05
CA2310845C (en) 2001-05-15
JPH08511536A (en) 1996-12-03
ES2341140T3 (en) 2010-06-15
DE122009000066I1 (en) 2010-02-04
CA2164866C (en) 2001-09-11
CA2332406C (en) 2005-01-04
DE69429619D1 (en) 2002-02-14
DE69435284D1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
CA2164866A1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
CA2164626A1 (en) Multiple botulinum toxins for treating neuromuscular disorders and conditions
CA2180011A1 (en) Botulinum toxins for treating sweating
GB9519661D0 (en) Fatty acid treatment
EP0945135A3 (en) Treatment of alzheimer's disease and modulation of immune system with Delta5-Androstenes
HU9402771D0 (en) Pharmaceutical compositions for wound healing and treatment of fibrotic disorders
CA2070823A1 (en) Neurologic agents for nasal administration to the brain
WO1994028922B1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
EP1014996A4 (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
CA2164291A1 (en) Methods and pharmaceutical compositions useful for treating neurological disorders
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
EP1019072A4 (en) Method for assisting in differential diagnosis and treatment of autistic syndromes
CA2289717A1 (en) Novel therapy for constipation
CA2184920A1 (en) Methods of diagnosing and treating preeclampsia
CA2154080A1 (en) Novel anticoagulant cofactor activity
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
EP0744176A3 (en) Methods for inhibiting bone loss
CA2216789A1 (en) Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
AU3733295A (en) Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
CA2159485A1 (en) Anti-oxydant alkylaryl polyether alcohol polymers
WO1996036324A3 (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
张安莉 et al. Clinical effect of acupuncture in the treatment of gastrokinetic disturbance
CA2239420A1 (en) Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders
WO1996029076A3 (en) Treatment of inflammatory bowel disorders with cotinine
CA2300666A1 (en) Method for treating dystonia with botulinum toxin type b

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140609